Arvinas, Inc.

0 products tracked · names used in filings: Arvinas, Inc.

Upcoming milestones

No upcoming milestones listed.

Recent milestones

Fri 05 Jun 2026🇺🇸 PDUFA datecompany-announced

VEPPANU: PDUFA target action date (ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of end)

Arvinas, Inc. (ARVN); vepdegestrant; status: met; "FDA approval was received in advance of FDA-assigned Prescription Drug User Fee Act (“PDUFA”) date of June 5, 2026."; filed 2026-05-01 · source

Fri 05 Jun 2026🇺🇸 PDUFA datecompany-announced

vepdegestrant: PDUFA target action date (ESR1-mutated ER+/HER2- advanced breast cancer previously treated with endocrine-based therapy)

Arvinas, Inc. (ARVN); vepdegestrant; NDA; status: set; "…Advance towards Prescription Drug User Fee Act (PDUFA) action date on June 5, 2026."; filed 2026-02-24 · source

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.